R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Senior Medical Director - Late Stage

Full-Time
$346k - $397k
Expert
MD
Redwood City, CA, USA
In Person
Biology & BiotechClinical Research Operations

About the job

Requirements
  • M.D. or equivalent international medical degree (MBBS or MBChB), with board certification or eligibility in Oncology or Hematology-Oncology; subspecialty training in thoracic malignancies is strongly preferred.
  • At least 13 years of experience in clinical development; Pharma R&D experience outside a clinical-development role may be considered based on transferable skills and responsibilities.
  • At least 5 years of late-stage clinical development experience within the biotechnology or pharmaceutical industry.
  • Demonstrated experience with medical data review and data cleaning for NDA or BLA filings and regulatory submissions.
  • Strong working knowledge of data cleaning, database-lock processes, and clinical data review.
  • Ability to lead cross-functional clinical teams and contribute to strategic development plans.
  • Written and verbal communication skills for scientific and regulatory audiences.
  • Extensive experience applying data-analysis and interpretation principles and techniques, including clinical relevance, in the pharmaceutical or biotechnology industry.
  • Experience independently generating trial designs; writing or amending protocols and informed consent forms; constructing appropriate case report forms; and coordinating cross-functionally.
  • In-depth therapeutic-area expertise and relevant clinical-trial experience, or clear ability to adapt using transferable skills.
  • Strong knowledge of medical aspects of Good Clinical Practice, International Council for Harmonisation guidelines, and relevant Food and Drug Administration, European Medicines Agency, and other guidelines and regulations.
  • Ability to work effectively and efficiently within cross-functional drug-development teams and integrate multiple perspectives into the Clinical Development Plan.
  • Experience authoring regulatory briefing packs, writing responses to Health Authority questions, and contributing to strategic approaches and cross-functional coordination for regulatory activities and interactions.
  • Demonstrated success driving cross-functional study-level strategy, including study design, feasibility, timeline and budget projections, and protocol amendments; ability to drive relevant discussions at internal decision-making bodies and governance forums.
  • Ability to build and maintain relationships and contribute to interactions with external key opinion leaders to optimize clinical programs, including advisory boards, individual engagements, and steering committees.
  • Experience engaging investigators to optimize clinical-trial conduct, including presenting at investigator meetings.
  • Ability to mentor team members; experience or clear potential as an effective line manager.
  • Ability to build and maintain relationships with internal and external stakeholders.
  • Strategic thinking and analytical skills to make data-driven decisions, assess trade-offs, and determine priorities and goals.
  • Written communication and business-presentation skills.
  • Ability to anticipate needs and assess and manage business and organizational risks.
  • Ability to work in a fast-paced, collaborative biotechnology environment.
Responsibilities
  • Serve as the clinical point of accountability for data integrity in ongoing and completed studies across the oncology portfolio.
  • Apply medical expertise to guide query resolution, outlier adjudication, and clinical-plausibility review during data cleaning.
  • Collaborate with clinical study teams to align protocol design, case report forms, and data standards with downstream regulatory submission requirements.
  • Lead clinical-science aspects of the Clinical Development Plan strategy and clinical documentation.
  • Represent the Clinical Development Plan on appropriate teams, sub-teams, and forums; oversee training of study-site personnel; act as the primary point of contact for program-level Clinical Development Plan questions; and oversee medical and safety data reviews and study reporting.
  • Partner with Regulatory Affairs, Biostatistics, Data Management, and Medical Writing to ensure clinical datasets, narratives, and summaries meet Food and Drug Administration, European Medicines Agency, and International Council for Harmonisation standards for NDA, BLA, and MAA filings.
  • Support the Medical Monitors Medical Lead and other team leads with clinical sections of regulatory dossiers, including Integrated Summary of Efficacy, Integrated Summary of Safety, and Clinical Study Reports.
  • Support preparation of responses to regulatory authorities and contribute to advisory committee briefing documents.
  • Drive end-to-end data-cleaning strategy, ensuring timely resolution of queries and reconciliation of safety, efficacy, and laboratory data.
  • Lead clinical-data-review meetings, escalate issues, and recommend solutions to maintain data reliability and consistency.
  • Take potential assignments to complex, high-priority strategic studies and perform responsibilities independently with self-directed leadership.
  • Work with Data Management, Medical Monitors, contract research organizations, and Clinical Operations to ensure site-level data collection, query resolution, and other activities align with submission requirements.
  • Partner with Pharmacovigilance to reconcile safety databases with clinical-trial datasets.
  • Align work cross-functionally with scientific, regulatory, and commercial objectives while executing the Clinical Development Plan.
  • Lead and mentor a cross-functional team of clinical-development professionals.
  • Oversee clinical-trial design and execution, including site selection, patient recruitment, data management, and regulatory compliance.
  • Establish and maintain relationships with clinical investigators, regulatory agencies, and key stakeholders.
  • Gather, analyze, and interpret clinical data; provide strategic insights to inform decisions and guide program development.
  • Manage clinical-development timelines, resource allocation, and milestone achievement.
  • Monitor scientific advancements and regulatory trends in clinical development.
Desired Qualifications
  • Subspecialty training in thoracic malignancies.
  • Experience enhancing or developing core and sub-team processes, structures, systems, tools, and other resources in the pharmaceutical or biotechnology industry.
  • Experience leading clinical-development contributions to major regulatory submissions, such as NDA, BLA, PIP, or PSP submissions; label negotiations; Breakthrough Therapy Designation; or accelerated review.
  • Ability to present a program’s clinical-development aspects to major health authorities, including the Food and Drug Administration and European Medicines Agency, by teleconference or in person; experience leading Health Authority interactions.
  • Ability to set the clinical-development strategy for CTA or EC submissions and responses to Health Authority questions.
  • Experience collaborating on enterprise-level strategic initiatives with internal and external partners and stakeholders, including clinical investigators, clinicians, scientists, key opinion leaders, development, research, business development, commercial, and legal groups, to achieve strategic outcomes.
  • Ability to influence and inspire teams and individuals.
  • Demonstrated courage and conviction and conflict-resolution skills.

About the company

Revolution Medicines develops targeted therapies for cancers caused by RAS mutations, which are found in about 30% of human cancers. The company’s products are small molecules called RAS(ON) inhibitors that work by blocking the active, cancer-promoting form of the RAS protein to stop tumor growth. Unlike older treatments that could only target a few specific mutations, this platform creates inhibitors that can address a much wider range of RAS-driven cancers. The company's goal is to advance these candidates through clinical trials to provide effective treatment options for patients with previously "undruggable" forms of cancer.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Get referred to Revolution Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approved RASONQUE on August 26, 2026, six months ahead of deadline.
  • RASolute 302 cut death risk 60% and doubled median overall survival to 13.2 months.
  • Royalty Pharma's June 2025 $2 billion package funds commercialization and global expansion through 2027.

What critics are saying

  • RASONQUE costs $39,800 monthly, inviting Medicare and commercial payer restrictions in 2026.
  • Revenue still depends overwhelmingly on one launch; any RASONQUE setback crushes the company.
  • AstraZeneca, Amgen, and Mirati pressure RAS programs; resistance or safety issues can erase the franchise.

What makes Revolution Medicines unique

  • RASONQUE became the first approved broad RAS(ON) inhibitor on August 26, 2026.
  • Revolution Medicines avoids companion diagnostics and treats metastatic PDAC with or without RAS mutations.
  • Its pipeline spans daraxonrasib, elironrasib, and zoldonrasib across pancreatic, lung, and colorectal cancers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
Asianet News
Oct 16th, 2026
VSTM stock clocks best day in 11 months after positive cancer drug trial update and multiple price-target hikes.

VSTM stock clocks best day in 11 months after positive cancer drug trial update and multiple price-target hikes. Published: Oct 16 2026, 03:00 AM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us * Alliance Global on Thursday raised its price target on VSTM to $22 from $18 and maintained a Buy rating. * RBC Capital analyst Leonid Timashev said that while VS-7375 tolerability is not as favorable as Revolution Medicines' experimental drug Zoldonrasib, the overall profile remains acceptable. * BTIG said VS-7375 could rival Revolution Medicines' approved drug Daraxonrasib in second-line metastatic pancreatic disease. Shares of Verastem Oncology (VSTM) jumped 20% on Thursday, clocking its best day since Nov. 2025, as analysts lifted price targets following a positive update on the company's experimental drug VS-7375 in second-line metastatic pancreatic ductal adenocarcinoma. On Wednesday, Verastem said that in its ongoing early-stage TARGET-D 101 trial, VS-7375 produced a 50% confirmed overall response rate in second-line metastatic pancreatic ductal adenocarcinoma at the 900 mg daily dose, along with responses in lung and colorectal cancers and a manageable safety profile dominated by low-grade gastrointestinal side effects. Verastem also added that the company has aligned with the U.S. Food and Drug Administration on a late-stage path in first-line metastatic pancreatic cancer using chemotherapy-free regimens, with the study expected to open by year-end. Wall street weighs in on VSTM. Alliance Global on Thursday subsequently raised its price target to $22 from $18 and maintained a Buy rating, describing the updated TARGET-D 101 data as showing a highly tolerable safety profile and efficacy that is in line with or better than other drugs in the same class and in development, potentially best-in-class. RBC Capital analyst Leonid Timashev increased the target to $19 from $14 while keeping an Outperform rating, calling the drug clearly active with hints of best-in-class efficacy in pancreatic ductal adenocarcinoma. He noted that while tolerability is not as favorable as one competitor, Revolution Medicines' experimental drug Zoldonrasib, the overall profile remains acceptable. BTIG raised its target to $24 from $18 and kept a Buy rating, saying the detailed update across second-line pancreatic cancer, second-line non-small cell lung cancer, and third-line colorectal cancer points to class-leading efficacy that could rival Revolution Medicines' approved drug Daraxonrasib in second-line metastatic pancreatic disease. Jefferies analyst Faisal Khurshid raised the price target to $13 from $11 and maintained a Buy rating. Aligning on a favorable late-stage trial path, he added, positions Verastem only about seven months behind competitors Revolution Medicines and Incyte in the race to develop drugs within the same class. CEO change and Capital raising. Verastem on Wednesday also priced a $250 million offering of common stock and pre-funded warrants at $8 per share to support VS-7375 development and general purposes, expected to close around October 15. The company further announced a planned CEO transition, with longtime executive Daniel Paterson retiring effective January 1, 2027, and board member Michael P. Bailey succeeding him. How did VSTM retail traders react? On Stocktwits, retail sentiment around VSTM stayed within 'extremely bullish' territory over the past 24 hours, while message volume stayed at 'extremely high' levels. "The more I watch it, the more constructive it looks," a Stocktwits user wrote about the stock. View this Stocktwits post Another user drew a parallel between VSTM's current rally and Iovance Biotherapeutics Inc (IOVA) stock's rally last month, which lasted for several days. View this Stocktwits post VSTM stock has gained 2o% year-to-date. For updates and corrections, email newsroom[at]stocktwits[dot]com.< Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New

pharmaphorum
Oct 16th, 2026
RevMed nears EU okay for pancreatic cancer drug Rasonque.

RevMed nears EU okay for pancreatic cancer drug Rasonque. Revolution Medicines is likely just weeks away from getting EU approval for its oral RAS inhibitor Rasonque as a treatment for pancreatic cancer, after the drug was recommended by the EMA's human medicines committee. The CHMP has backed Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least one previous treatment - the same indication that was cleared by the US FDA in August. The positive opinion is based on phase 3 results with Rasonque from the RASolute 302 trial that caused a stir at this year's ASCO cancer congress, with a doubling in overall survival (OS) and progression-free survival (PFS) compared to chemotherapy and big improvements in quality-of-life scores. The outcome was remarkable, particularly as metastatic pancreatic adenocarcinoma is a notoriously difficult-to-treat cancer with a low survival rate. "People with metastatic pancreatic adenocarcinoma whose disease has worsened after prior treatment have limited treatment options and a poor prognosis," said the EMA, which granted Rasonque an expedited, phased review - which cut its assessment time from 210 days to less than 150 days - as a high-priority medicine that could address this unmet medical need. "Given the seriousness of the disease, [and] the limited efficacy and substantial toxicity of standard-of-care chemotherapy, there is a need for better treatment options for these patients." The RAS protein is a key driver for many tumour types, including the majority of pancreatic cancers. For many years, it was considered an 'undruggable' target, until RevMed solved the problem with daraxonrasib, constructed by binding RAS to a protein called cyclophilin A to form a complex that can attach to the RAS protein and block its activity. The pan-RAS category is pretty crowded, with more than a dozen drug candidates in clinical testing, but Revolution seems to have a healthy first-mover advantage with other trials underway in pancreatic adenocarcinoma, as well as non-small cell lung cancer (NSCLC). Those include the RASolute 303 trial in first-line pancreatic cancer, RASolute 304 in adjuvant treatment of tumours treatable with surgery, and RASolve 301 looking at first-, second-, and third-line treatment of metastatic NSCLC. There has been some noise about Rasonque's slightly lower tumour response rate in patients with KRAS G12D mutations in RASolute 302, which analysts have suggested could open the door to competition from selective drugs like Verastem Oncology's VS-7375, which is in phase 3 for pancreatic cancer. RevMed is, however, also developing a KRAS G12D-selective inhibitor, zoldonrasib, both as a monotherapy and in combination with Rasonque. 16 October, 2026

Yahoo Finance
Oct 15th, 2026
Revolution Medicines and Oruka double in 2026, beating Magnificent Seven; analysts see up to 95% upside

Two biotech stocks, Revolution Medicines and Oruka Therapeutics, have more than doubled this year, beating most of the Magnificent Seven tech group. Wall Street's average price targets suggest further gains. Revolution Medicines won approval for Rasonque, a treatment for certain patients with metastatic pancreatic cancer. In a Phase 3 study, patients lived a median 13.2 months, against 6.7 months on chemotherapy. Its market cap is about $41 billion, and its average price target of $259.14 implies 35.7% upside. Oruka Therapeutics has no approved drug. Its psoriasis candidate, ORKA-001, could be dosed once or twice a year, and has shown strong results in a Phase 2a study. The average price target of $155 implies 95% upside, but the drug has not entered Phase 3 trials.

Yahoo Finance
Oct 15th, 2026
EU regulator backs Revolution Medicines' RASONQUE for pancreatic cancer after 60% lower death risk

Revolution Medicines (Nasdaq: RVMD) said the European Medicines Agency's Committee for Medicinal Products for Human Use has backed RASONQUE (daraxonrasib), an oral tablet for adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy. If the European Commission approves it, RASONQUE would be the first broad RAS-targeted treatment option in the European Union for these patients. The opinion followed an expedited review under the agency's Cancer Medicines Pathfinder project. In the Phase 3 RASolute 302 trial, the drug cut the risk of death by 60% compared with chemotherapy. Median overall survival was 13.2 months, against 6.7 months for chemotherapy. The US Food and Drug Administration approved the drug on August 26, 2026.

PR Newswire
Oct 14th, 2026
Cancer drug spending to top $400B by 2028 as RAS-targeted therapies reach pancreatic, colorectal cancers

Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute. The US accounts for roughly 46% of the total. On August 26, the US Food and Drug Administration (FDA) approved Revolution Medicines' RASONQUE (daraxonrasib), the first broad RAS-targeted medicine for metastatic pancreatic cancer. In a Phase 3 trial, median overall survival was 13.2 months, against 6.7 months with chemotherapy. Colorectal cancer is also drawing attention. Oncolytics Biotech expects interim data from Part A of its REO 033 study of pelareorep by year-end. Exelixis saw the FDA extend its review of zanzalintinib for metastatic colorectal cancer to March 3, 2027.